allosteric SHP2 inhibitors (Astex Pharmaceuticals/Taiho Pharmaceutical)

N/A

Report date: 2025/03/14 16:30:35
NME

Base Information

Drug Nameallosteric SHP2 inhibitors (Astex Pharmaceuticals/Taiho Pharmaceutical)
Drug Alias Nameallosteric inhibitors of Src homology region 2-containing protein tyrosine phosphatase 2 (Astex Pharmaceuticals/Taiho Pharmaceutical)SHP2/KRAS inhibitors (Merck & Co)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitorsSrc homology phosphotyrosyl phosphatase 2 inhibitors
TargetsSrc homology phosphotyrosyl phosphatase 2GTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co IncTaiho Pharmaceutical Co Ltd
Inactive CompaniesAstex Pharmaceuticals Inc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A